| Literature DB >> 33180882 |
Huiwen Zheng1, Heng Li1, Lei Guo1, Yan Liang1, Jing Li1, Xi Wang1, Yunguang Hu1, Lichun Wang1, Yun Liao1, Fengmei Yang1, Yanyan Li1, Shengtao Fan1, Dandan Li1, Pingfang Cui1, Qingling Wang1, Haijing Shi1, Yanli Chen1, Zening Yang1, Jinling Yang1, Dong Shen1, Wei Cun1, Xiaofang Zhou2, Xingqi Dong3, Yunchuan Wang1, Yong Chen1, Qing Dai1, Weihua Jin1, Zhanlong He1, Qihan Li1, Longding Liu1.
Abstract
The COVID-19 has emerged as an epidemic, causing severe pneumonia with a high infection rate globally. To better understand the pathogenesis caused by SARS-CoV-2, we developed a rhesus macaque model to mimic natural infection via the nasal route, resulting in the SARS-CoV-2 virus shedding in the nose and stool up to 27 days. Importantly, we observed the pathological progression of marked interstitial pneumonia in the infected animals on 5-7 dpi, with virus dissemination widely occurring in the lower respiratory tract and lymph nodes, and viral RNA was consistently detected from 5 to 21 dpi. During the infection period, the kinetics response of T cells was revealed to contribute to COVID-19 progression. Our findings implied that the antiviral response of T cells was suppressed after 3 days post infection, which might be related to increases in the Treg cell population in PBMCs. Moreover, two waves of the enhanced production of cytokines (TGF-α, IL-4, IL-6, GM-CSF, IL-10, IL-15, IL-1β), chemokines (MCP-1/CCL2, IL-8/CXCL8, and MIP-1β/CCL4) were detected in lung tissue. Our data collected from this model suggested that T cell response and cytokine/chemokine changes in lung should be considered as evaluation parameters for COVID-19 treatment and vaccine development, besides of observation of virus shedding and pathological analysis.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33180882 PMCID: PMC7660522 DOI: 10.1371/journal.ppat.1008949
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Fig 1Experimental schedule and clinical signs in rhesus macaques inoculated with SARS-CoV-2.
(A) Schedule of viral inoculation and necropsies. (B) Monitoring of the body temperature of infected animals for 27 days. (C) Animals were scored for 27 days, and their mean clinical score ±SD was calculated.
Fig 2Viral shedding and viremia in rhesus macaques inoculated with SARS-CoV-2.
Oropharyngeal (A), nasal (B), and rectal (C) swab samples and blood samples (D) were collected for 27 days. Of note, 2 animals were euthanized on 3, 5 and 21 dpi, and 3 animals were euthanized on 7 and 9 dpi; thus, samples were reduced in the plots. RNA was extracted, and the viral load was determined as copies per 100 μl. The dashed line represents the detected threshold.
Fig 3Viral load in tissues of rhesus macaques inoculated with SARS-CoV-2.
Necropsy tissue samples of rhesus macaques were collected on 3, 5, 7, 9 and 21 dpi. RNA was extracted, and viral load was detected by qRT-PCR as copies per 100 mg tissue in (A) lungs and tracheas; (B) LNs; (C) CNS; and (D) other tissues. Control: the archived normal tissues. Error bars represent the SD.
Fig 4Histopathological changes in rhesus macaques inoculated with SARS-CoV-2.
Necropsy tissue samples of rhesus macaques were collected on 3, 5, 7, 9 and 21 dpi, stained with H&E for histopathological evaluation, or labeled with anti-N antigen antibody for IHC analysis. (A) Lung tissue samples showed mild to marked acute interstitial pneumonia demonstrated by diffuse alveolar damage and edema (black arrow), alveolar thickening (green arrow), large numbers of neutrophils, macrophages, and infiltration (blue arrow). Anti-SARS-CoV-2 antigen for IHC revealed viral N antigen in alveolar pneumocytes. (B) Trachea tissues showed damage to epithelial cells (black arrow). (C) LN samples showed enlarged germinal centers (blue arrow) in response to viral infection. IHC reveals viral N antigen within LNs. (D) Lung (E) trachea and (F) LN IHC analyses (magnification: 400×). Yellow scale bar, 100μl; Black scale bar, 50μl. Control: the archived normal tissues.
Fig 5Analysis of ACE2 related to SARS-CoV-2 infection in rhesus macaques by confocal immunofluorescence assay.
Human ACE2 was detected with goat anti-human ACE2 (red) antibody followed by Alexa Fluor 647 dye-conjugated goat anti-rabbit IgG. Viral N antigen (yellow) was detected with a mouse antibody against the SARS-CoV-2 N protein followed by Alexa Flour 555 dye-conjugated goat anti-mouse IgG. Nuclei were stained with DAPI (magnification: 630×.). Control: the archived normal tissues.
Fig 6Immune analysis of SARS-CoV-2-infected rhesus macaques.
(A) Lymphocyte phenotyping by T, B, and NK cells in PBMCs (upper row) and lung tissues (lower row). (B) T helper cells for IL-4, IFN-γ, IL-17 and FOXP3 expression gated in CD4+ cells from PBMCs (upper row) and lung tissues (lower row). (C)Treg cells for CD25 expression gated in CD4+CD127- cells from PBMC(upper row), and lung tissues(Lower row). Control: the archived normal lung tissues. D0: Samples from day 0(samples prior to infection)were used as controls.”*”, p<0.05; “ns”, p>0.05.
Fig 7Changes of cytokines/chemokines concentrations during the SARS-COV-2 infected process.
Cytokine cytometric bead arrays were performed to measure the concentrations of 23 cytokines and chemokine. The fold change of cytokines of each samples = The concentration value of each experimental well /the concentration value of the control well. The concentration below the detection line is calculated as the concentration of limit of detection. Three multiple wells are set for each sample, and the mean±SD are finally calculated. Control: the archived normal lung tissues.
Fig 8Neutralizing antibody level and ELISpot analysis of rhesus macaques infected with SARS-CoV-2.
(A) Neutralizing antibodies against SARS-CoV-2 were titered on Vero cells at 100 TCID50 virus. (B) S and N protein-specific IFN-γ+ secretion T cells were numbered on precoated PVDF plates by an ELISpot reader. Compared with controls,”*”, p<0.05; “ns”, p>0.05.
Host immune response and pathological observation in non-human primates of SARS-CoV-2 infection.
| Monkey species/age | Inoculation Route/Dose | Clinical Symptoms | Gross pathology examinations of lung | Microscopic pathology examinations of lung | Host immune response Refs | |||
|---|---|---|---|---|---|---|---|---|
| Rhesus macaque 8–12 months | IN; 2×105TCID50 | less activity and loss of appetite; fever | Red lesions, severe scattered pleural adhesions | Interstitial infiltration, diffused alveolar damage, thickening of alveolar, Alveoli contained mononuclear/macrophage and neutrophils accumulation | This study | |||
| macaca fascicularis 4-5years; 15-20years | IN, IT; 107TCID50 | Nasal discharge; No significant weight loss | foci of pulmonary consolidation | Hyaline membranes, Alveolar edema, Leukocyte infiltration | No data | No data | No data | 19 |
| Rhesus macaque 4–6 years | IN, IT, oral, Oc; total 6ml of 4×105 TCID50/ml | Irregular respiratory patterns change; piloerection; reduced appetite; hunched posture; pale appearance; cough; weight loss; fever; | Varying degrees of gross lung lesions | Interstitial pneumonia, edema fluid, fibrin, macrophages and neutrophils accumulation | No data | 1dpi:IL-1ra↑,IL-6↑,IL-10↑,IL-15↑,MCP-1↑,MIP-1b↑; | No data | 20 |
| Rhesus macaque 6-11years | IT; 7×106CCID50 | Reduced appetite | large patchy hemorrhage; red dark foci; consolidation | Necrosis, collapse and fibrosis, extensive fibroblast proliferation, inflammatory cells infiltration | No data | No data | No data | 22 |
| Rhesus macaques 3–5 years; 15 years | IT; 106 TCID50 | Weight loss, fever, Asthenia, | patchy lesions; ground-glass opacities | Pneumonia, inflammatory cells infiltration | No data | No data | 21 | |
| Rhesus macaques macaca fascicularis, Callithrix jacchus | IT, Oc, IN; 1×106 -4.75×106 PFU | High body temperature, loss of body weight; | nodules, masses, and interstitial patterns | Pulmonary septum, the infiltration of inflammatory cells, diffuse hemorrhage, necrosis | Eight cytokines(G-CSF,IL-1A,IL-8,IL-15,IL-18,MCP-1,MIP-1B, and sCD40L) were detected in most of the infected monkeys | No data | 23 | |
Note: IN, intranasal; IT, intratracheal; OC, ocular; PFU, plaque-forming units; TCID50, 50% tissues culture infectious dose; Refs, references.; ↑,increasing;↓,decreasing; (-),return to normal level
a: 0 dpi samples (samples prior to infection) as controls.
b: Archived normal tissues as controls
Viral shedding and distribution in non-human primates of SARS-CoV-2 infection.
| Monkey species | Viral duration/peak viral load | Viremia | Virus distribution in tissues | Infectious Virus shedding | Refs | ||
|---|---|---|---|---|---|---|---|
| Nasal swabs | Oropharyngeal swabs | Rectal swabs | |||||
| Rhesus macaque | 1-27dpi, 7.5×105 | 2-14dpi, 8.7×104 | 9-27dpi, 1.9×105 | On 5dpi, | Lung, Trachea, Intestine, CNS, Trachea LN, Neck LN, Lung LN, Kidney, Liver, Spleen, Heart, Testical | Rectal swabs | This study |
| macaca fascicularis | 1-18dpi, 103.4–104.7 TCID50 equivalent/ml | 1-10dpi, 102.8–103.9 TCID50 equivalent/ml | On 14dpi, | No viremia | Respiratory tissues, ileum, colon, tonsil. | Throat swabs, Nasal swab, | 19 |
| Rhesus macaque | 1-15dpi, about 104−108 | 1-15dpi, about 104−108 | 3-17dpi, about 102−105 | No viremia | Respiratory tract tissues, Stomach, Ileum, Colon, Cecum, Cervical LN, Mediastinal LN, Conjunctiva, Heart, Tonsil | Nose swabs;Balf fluid; Lung; | 20 |
| Rhesus macaque | 1-9dpi, about 104−107 | 1-11dpi 2.08×104–3.6×107 | 2-11dpi, about 105 | No viremia | Lung, Trachea and bronchus tract | Nasal swabs, Oropharyngeal swabs | 22 |
| Rhesus macaques | 3-11dpi, about 104−108 | 3-11dpi, about 104−108 | 3-11dpi, about 104−106 | No data | lung | no data | 21 |
| Macaca mulatta/ macaca fascicularis/ Callithrix jacchus | 2-21dpi, ~5.0×1011 | 2-17dpi,21dpi Variously in different groups | 2-14dpi,18dpi,21dpi; Variously in different groups | 2-10dpi | Lung, Trachea, Bronchus, Stomach, Rectum, cerebrospinal fluid, Intestine Ln, hilar lymph node, Bladder, Spleen,et al. | No data | 23 |
Abbreviations: LN, lymph nodes; Refs, references.
a SARS-COV-2 RNA was determined by qRT-PCR, copies/ml
Primers for different kinds of cytokine and chemokine genes.
| Primer | Sequence (5’-3’) |
|---|---|
| IL-8-F | ttttgccaaggagtgctaaaga |
| IL-8-R | aaccctctgcacccagttttc |
| IFN-α-F | gcctcgccctttgctttact |
| IFN-α-R | ctgtgggtctcagggagatca |
| IFN-β-F | atgaccaacaagtgtctcctcc |
| IFN-β-R | ggaatccaagcaagttgtagctc |
| IFN-r-F | tcggtaactgacttgaatgtcca |
| IFN-r-R | tcgcttccctgttttagctgc |
| IL-1β-F | atgatggcttattacagtggcaa |
| IL-1β-R | gtcggagattcgtagctgga |
| IL-2-F | tacaagaacccaaactgactcg |
| IL-2-R | acatgaaggtagtctcactgcc |
| IL-4-F | ccaactgcttccccctctg |
| IL-4-R | tctgttacggtcaactcggtg |
| IL-6-F | actcacctcttcagaacgaattg |
| IL-6-R | ccatctttggaaggttcaggttg |
| IL-17A-F | tcccacgaaatccaggatgc |
| IL-17A-R | ggatgttcaggttgaccatcac |
| IL-22-F | gcttgacaagtccaacttcca |
| IL-22-R | gctcactcatactgactccgt |
| TNF-a-F | cctctctctaatcagccctctg |
| TNF-a-R | gaggacctgggagtagatgag |